Lee WJ, Lee DW, Kim CH, et al. Pompholyx with bile-coloured vesicles in a patient with jaundice: are sweat ducts involved in the development of pompholyx?. J Eur Acad Dermatol Venereol. 2010 Feb. 24(2):235-6. [QxMD MEDLINE Link].
Kontochristopoulos G, Gregoriou S, Agiasofitou E, Nikolakis G, Rigopoulos D, Katsambas A. Letter: regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum toxin-A. Dermatol Surg. 2007 Oct. 33(10):1289-90. [QxMD MEDLINE Link].
Stuckert J, Nedorost S. Low-cobalt diet for dyshidrotic eczema patients. Contact Dermatitis. 2008 Dec. 59(6):361-5. [QxMD MEDLINE Link].
Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology. 2005 Apr 15. 209(2):101-7. [QxMD MEDLINE Link].
Shenefelt PD. Update on psychodermatological disorders. Expert Rev Dermatol. 2010 Feb. 5(1):95-107.
Doyle C, Eustace K. Pompholyx as a side effect of intravenous immunoglobulin (IVIg). BMJ Case Rep. 2022 Mar 30. 15 (3):[QxMD MEDLINE Link].
Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2011 May 19. [QxMD MEDLINE Link].
Kotan D, Erdem T, Acar BA, Boluk A. Dyshidrotic eczema associated with the use of IVIg. BMJ Case Rep. 2013 Feb 15. 2013:[QxMD MEDLINE Link]. [Full Text].
Lee KC, Ladizinski B. Dyshidrotic eczema following intravenous immunoglobulin treatment. CMAJ. 2013 Aug 6. 185(11):E530. [QxMD MEDLINE Link]. [Full Text].
Brazzelli V, Grassi S, Savasta S, Ruffinazzi G, Carugno A, Barbaccia V, et al. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case. Int J Immunopathol Pharmacol. 2014 Jan-Mar. 27(1):127-30. [QxMD MEDLINE Link].
Chen JJ, Liang YH, Zhou FS, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol. 2006 Feb. 126(2):300-4. [QxMD MEDLINE Link].
Molin S, Vollmer S, Weiss EH, Ruzicka T, Prinz JC. Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. Br J Dermatol. 2009 Oct. 161(4):801-7. [QxMD MEDLINE Link].
Soler DC, Bai X, Ortega L, Pethukova T, Nedorost ST, Popkin DL, et al. The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx. Med Hypotheses. 2015 May. 84 (5):498-503. [QxMD MEDLINE Link].
Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol. 2007 Dec. 143(12):1504-8. [QxMD MEDLINE Link].
Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol. 2004 Jan. 50(1):55-60. [QxMD MEDLINE Link].
Tamer E, Ilhan MN, Polat M, Lenk N, Alli N. Prevalence of skin diseases among pediatric patients in Turkey. J Dermatol. 2008 Jul. 35(7):413-8. [QxMD MEDLINE Link].
Nalluri R, Rhodes LE. Photoaggravated pompholyx. Photodermatol Photoimmunol Photomed. 2016 Feb 12. [QxMD MEDLINE Link].
Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis. 2006 Dec. 17(4):165-81. [QxMD MEDLINE Link].
Magina S, Barros MA, Ferreira JA, Mesquita-Guimaraes J. Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. Am J Contact Dermat. 2003 Jun. 14(2):63-8. [QxMD MEDLINE Link].
Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology. 1999 Sep 22. 53(5):1154-5. [QxMD MEDLINE Link].
Llombart M, Garcia-Abujeta JL, Sanchez-Perez RM, Hernando de Larramendi C. Pompholyx induced by intravenous immunoglobulin therapy. J Investig Allergol Clin Immunol. 2007. 17(4):277-8. [QxMD MEDLINE Link].
Colebunders R, Zolfo M, Lynen L. Severe dyshidrosis in two patients with HIV infection shortly after starting highly active antiretroviral treatment. Dermatol Online J. 2005 Aug 1. 11(2):31. [QxMD MEDLINE Link].
MacConnachie AA, Smith CC. Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. Acta Derm Venereol. 2007. 87(4):378-9. [QxMD MEDLINE Link].
Molin S, Diepgen TL, Ruzicka T, Prinz JC. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. Clin Exp Dermatol. 2011 Aug. 36(6):595-601. [QxMD MEDLINE Link].
Vocks E, Plotz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology. 1999. 198(3):265-9. [QxMD MEDLINE Link].
Hsu CY, Wang YC, Kao CH. Dyshidrosis is a risk factor for herpes zoster. J Eur Acad Dermatol Venereol. 2015 Apr 27. in press. [QxMD MEDLINE Link].
Yasuda M, Miyachi Y, Utani A. Two cases of dyshidrosiform pemphigoid with different presentations. Clin Exp Dermatol. 2009 Jul. 34(5):e151-3. [QxMD MEDLINE Link].
Veien NK. Bullous pemphigoid masquerading as recurrent vesicular hand eczema. Acta Derm Venereol. 2010. 90(1):4-5. [QxMD MEDLINE Link].
Chang YY, van der Velden J, van der Wier G, et al. Keratolysis exfoliativa (dyshidrosis lamellosa sicca): a distinct peeling entity. Br J Dermatol. 2012 Nov. 167(5):1076-84. [QxMD MEDLINE Link].
Bittencourt AL, Mota K, Oliveira RF, Farré L. A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009 Dec. 31(8):834-7. [QxMD MEDLINE Link].
Bittencourt AL, Mota K, Oliveira RF, Farré L. A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009 Dec. 31(8):834-7. [QxMD MEDLINE Link].
National Institute for Clinical Excellence. Frequency of application of topical corticosteroids for atopic eczema. London, England: National Institute for Clinical Excellence (NICE); 2004. 34.
Wollina U, Abdel Naser MB. Pharmacotherapy of pompholyx. Expert Opin Pharmacother. 2004 Jul. 5(7):1517-22. [QxMD MEDLINE Link].
Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008 Oct 8. CD006135. [QxMD MEDLINE Link].
Capella GL. Topical khellin and natural sunlight in the outpatient treatment of recalcitrant palmoplantar pompholyx: report of an open pilot study. Dermatology. 2005. 211(4):381-3. [QxMD MEDLINE Link].
Odia S, Vocks E, Rakoski J, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol. 1996 Nov. 76(6):472-4. [QxMD MEDLINE Link].
Markantoni V, Kouris A, Armyra K, Vavouli C, Kontochristopoulos G. Remarkable improvement of relapsing dyshidrotic eczema after treatment of coexistant hyperhidrosis with oxybutynin. Dermatol Ther. 2014 Nov-Dec. 27(6):365-8. [QxMD MEDLINE Link].
Koldys KW, Meyer RP. Biofeedback training in the therapy of dyshidrosis. Cutis. 1979 Aug. 24(2):219-21. [QxMD MEDLINE Link].
Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. 2004 Jan. 50(1):68-72. [QxMD MEDLINE Link].
Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. 2003 Nov. 28(6):584-7. [QxMD MEDLINE Link].
Tzaneva S, Kittler H, Thallinger C, Honigsmann H, Tanew A. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed. 2009 Apr. 25(2):101-5. [QxMD MEDLINE Link].
Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007 Feb. 23(1):10-4. [QxMD MEDLINE Link].
Schurmeyer-Horst F, Luger TA, Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology. 2007. 214(1):99-100. [QxMD MEDLINE Link].
Wollina U. Pompholyx: what's new?. Expert Opin Investig Drugs. 2008 Jun. 17(6):897-904. [QxMD MEDLINE Link].
Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002 Jan. 16(1):40-2. [QxMD MEDLINE Link].
Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999 Apr. 40(4):612-4. [QxMD MEDLINE Link].
Petersen CS, Menne T. Cyclosporin A responsive chronic severe vesicular hand eczema. Acta Derm Venereol. 1992 Nov. 72(6):436-7. [QxMD MEDLINE Link].
Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. 2006 Jan. 31(1):145-6. [QxMD MEDLINE Link].
Menne T, Kaaber K. Treatment of pompholyx due to nickel allergy with chelating agents. Contact Dermatitis. 1978 Oct. 4(5):289-90. [QxMD MEDLINE Link].
Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol. 2000 Sep-Oct. 1(5):307-14; discussion 315-6. [QxMD MEDLINE Link].
Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004 Dec. 140(12):1453-9. [QxMD MEDLINE Link].
Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol. 2006 Oct. 155(4):856-7. [QxMD MEDLINE Link].
Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis. 2005 Jul. 76(1):69-73. [QxMD MEDLINE Link].
Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol. 2002 Dec. 47(6):969-70. [QxMD MEDLINE Link].
Bassiri-Tehrani S, BA BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol. 2002 Feb. 41(2):104-6. [QxMD MEDLINE Link].
Bissonnette R, Maares J, Shear N. Alitretinoin is Well Tolerated in the Treatment of Severe Chronic Hand Eczema. Poster P1409 presented a the 68th Annual Meeting of American Academy of Dermatology. March 5-9, 2010, Miami, Fla. J Am Acad Dermatol. Mar 2010. 62(3 Supp):AB51.
Lynde C, Haarsch M, Poulin Y. Alitretinoin is Effective in Clearing Severe Crhonic Hand Ezcema. Poster P1405 presented a the 68th Annual Meeting of American Academy of Dermatology. March 5-9, 2010, Miami, Fla. J Am Acad Dermatol. Mar 2010. 62(3 Supp):AB50.
Gall RA, Peters JD, Brinker AJ. Two Cases of Recalcitrant Dyshidrotic Eczema Treated With Dupilumab. J Drugs Dermatol. 2021 May 1. 20 (5):558-559. [QxMD MEDLINE Link]. [Full Text].
Gladys TE, Maczuga S, Flamm A. Characterizing demographics and cost of care for dyshidrotic eczema. Contact Dermatitis. 2022 Feb. 86 (2):107-112. [QxMD MEDLINE Link].